Tonix Pharmaceuticals Holding Corp. (TNXP)
13.14
-0.23
(-1.72%)
USD |
NASDAQ |
Sep 04, 16:00
13.33
+0.19
(+1.45%)
After-Hours: 20:00
Tonix Pharmaceuticals SG&A Expense (TTM) : 125.96M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 125.96M |
| March 31, 2026 | 106.20M |
| December 31, 2025 | 87.68M |
| September 30, 2025 | 67.59M |
| June 30, 2025 | 49.60M |
| March 31, 2025 | 40.90M |
| December 31, 2024 | 40.10M |
| September 30, 2024 | 36.14M |
| June 30, 2024 | 37.14M |
| March 31, 2024 | 36.67M |
| December 31, 2023 | 34.75M |
| September 30, 2023 | 31.18M |
| June 30, 2023 | 29.86M |
| March 31, 2023 | 29.59M |
| December 31, 2022 | 30.22M |
| September 30, 2022 | 29.42M |
| June 30, 2022 | 27.49M |
| March 31, 2022 | 26.16M |
| December 31, 2021 | 23.56M |
| September 30, 2021 | 21.22M |
| June 30, 2021 | 18.95M |
| March 31, 2021 | 17.14M |
| December 31, 2020 | 14.35M |
| September 30, 2020 | 12.47M |
| June 30, 2020 | 12.12M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.86M |
| December 31, 2019 | 10.64M |
| September 30, 2019 | 10.18M |
| June 30, 2019 | 9.623M |
| March 31, 2019 | 9.347M |
| December 31, 2018 | 8.764M |
| September 30, 2018 | 7.78M |
| June 30, 2018 | 6.73M |
| March 31, 2018 | 6.67M |
| December 31, 2017 | 6.149M |
| September 30, 2017 | 6.27M |
| June 30, 2017 | 6.486M |
| March 31, 2017 | 6.09M |
| December 31, 2016 | 7.236M |
| September 30, 2016 | 8.171M |
| June 30, 2016 | 8.494M |
| March 31, 2016 | 8.787M |
| December 31, 2015 | 9.211M |
| September 30, 2015 | 9.775M |
| June 30, 2015 | 10.23M |
| March 31, 2015 | 10.29M |
| December 31, 2014 | 9.039M |
| September 30, 2014 | 8.191M |
| June 30, 2014 | 7.429M |
| March 31, 2014 | 6.596M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Exelixis, Inc. | 533.92M |
| Inovio Pharmaceuticals, Inc. | 30.77M |
| Heron Therapeutics, Inc. | 104.50M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |